Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

NCT06276868 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

71

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Dalcilib+letrozole+HP treatment group

Sponsor

Henan Cancer Hospital